Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can be fraught with risk.
Increasing regulatory practice and the need for ever-evolving technologies means smaller companies need a supporting CDMO that matches the demanding requirements.
In our latest Q&A, Senior Director David Hall navigates the trends and risks in areas including technical challenges and regulatory compliance.
Download today for insights on how to achieve the best return from your next project.
